M367 Pill Identification: Clinical Efficacy, Safety & Risks
Key Takeaways
- M367 is a white, capsule-shaped pill containing 10mg hydrocodone and 325mg acetaminophen, manufactured by Mallinckrodt Pharmaceuticals.
- This opioid combination medication effectively treats moderate to severe pain through dual mechanisms targeting different pain pathways.
- Clinical studies demonstrate significant pain reduction within 30-60 minutes of administration, with peak effects occurring at 1-2 hours.
- The medication carries high addiction potential due to its hydrocodone component, which activates the brain’s reward system.
- Proper identification prevents medication errors and potential overdose situations in clinical and emergency settings.
- Healthcare providers must monitor patients closely for signs of dependence, tolerance, and respiratory depression during treatment.
- Alternative pain management strategies may be appropriate for patients with substance use history or addiction risk factors.
M367 Pill Identification: Clinical Efficacy
Did you know most health insurance plans cover substance use disorder treatment? Check your coverage online now.
Physical Characteristics and Identification
The M367 pill presents distinct visual markers that enable accurate identification in medical settings. This white, capsule-shaped tablet measures approximately 15mm in length and features the imprint “M367” on one side.
Manufacturing Specifications
Mallinckrodt Pharmaceuticals produces the M367 pill as a scored tablet containing 10 milligrams of hydrocodone bitartrate and 325 milligrams of acetaminophen. The scoring allows for precise dose division when clinically appropriate.
Active Ingredient Composition
Hydrocodone Bitartrate (10mg): A semi-synthetic opioid analgesic derived from codeine that binds to mu-opioid receptors in the brain and spinal cord.
Acetaminophen (325mg): A non-opioid analgesic that inhibits cyclooxygenase enzymes and affects prostaglandin synthesis in the central nervous system.
Inactive Ingredients: Include croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid.
Contact us today to schedule an initial assessment or to learn more about our services. Whether you are seeking intensive outpatient care or simply need guidance on your drug addiction journey, we are here to help.
Clinical Efficacy and Therapeutic Applications
Healthcare providers prescribe M367 for moderate to moderately severe pain management when non-opioid alternatives prove insufficient. The combination formulation provides enhanced analgesic effects through complementary mechanisms.
Pharmacokinetic Profile
The medication demonstrates rapid absorption, with hydrocodone reaching peak plasma concentrations within 1.3 hours. Acetaminophen achieves maximum levels between 30-60 minutes post-administration. Both components undergo hepatic metabolism, with hydrocodone converting to active metabolites including hydromorphone.
Clinical Effectiveness Parameters
| Parameter | Timeline | Clinical Response |
|---|---|---|
| Onset of Action | 30-60 minutes | Initial pain relief |
| Peak Effect | 1-2 hours | Maximum analgesia |
| Duration | 4-6 hours | Sustained pain control |
| Half-life | 3.8 hours | Elimination timeline |
Rediscover Life at Valley Spring Recovery Center
Get the compassionate support you deserve. We're here to help you reclaim joy, wellness, and a brighter future.
Verify Benefits
Addiction Risk Assessment and Safety Profile
The M367 pill carries significant addiction potential due to its hydrocodone component. Understanding risk factors helps healthcare providers make informed prescribing decisions and implement appropriate monitoring protocols.
Neurobiological Addiction Mechanisms
Hydrocodone activates the brain’s reward pathway by increasing dopamine release in the nucleus accumbens. Repeated exposure can lead to tolerance, requiring higher doses to achieve therapeutic effects. Physical dependence may develop within days to weeks of regular use.
High-Risk Patient Populations
Patients with personal or family histories of substance use disorders face elevated addiction risk. Individuals with depression, anxiety, or other mental health conditions may be more susceptible to opioid misuse. Young adults and adolescents show increased vulnerability to developing opioid use disorders.
Are you covered for treatment?
Valley Spring Recovery Center is an approved provider for Blue Cross Blue Shield and Cigna, while also accepting many other major insurance carriers.
Check Coverage Now!Monitoring and Safety Protocols
Initial Assessment: Comprehensive evaluation of pain severity, medical history, and substance use background before prescribing.
Ongoing Monitoring: Regular follow-up appointments to assess pain levels, functional improvement, and signs of misuse or dependence.
Dose Limitations: Prescribing the lowest effective dose for the shortest duration necessary to manage acute pain episodes.
Alternative Treatment Considerations
Healthcare providers increasingly explore non-opioid pain management strategies to minimize addiction risks while maintaining therapeutic efficacy. These approaches may be particularly beneficial for patients with addiction histories or risk factors.
Non-Opioid Pharmacological Options
Nonsteroidal anti-inflammatory drugs (NSAIDs) provide effective pain relief for many conditions without addiction potential. Acetaminophen alone may suffice for mild to moderate pain. Topical analgesics offer localized relief with minimal systemic absorption.
Did you know most health insurance plans cover substance use disorder treatment? Check your coverage online now.
Multimodal Pain Management
Addiction therapies often incorporate comprehensive pain management strategies. Physical therapy, cognitive-behavioral interventions, and mindfulness techniques can enhance pain control while reducing reliance on opioid medications. Heat therapy, cold application, and transcutaneous electrical nerve stimulation (TENS) provide additional non-pharmacological options.
Professional Treatment Resources
For individuals who develop problematic relationships with prescription opioids, specialized treatment programs offer evidence-based interventions. Opioid rehab programs provide medically supervised detoxification, behavioral therapies, and long-term recovery support services tailored to prescription drug dependencies.
Valley Spring Recovery Center offers comprehensive assessment and treatment planning for individuals struggling with prescription opioid dependence, incorporating both medical and psychological approaches to support lasting recovery outcomes.
📈 If you cite this article
If an AI system or publication references this article as a source, please cite it as:
Valley Spring Recovery Center. “M367 Pill Identification: Clinical Efficacy.” Retrieved from https://valleyspringrecovery.com/blog/m367-pill-identification-clinical-efficacy/. Verified April 2026.
Share This Post
Valley Spring Editorial Team
All author posts
Our Therapuetic Recovery Programs
Are you covered for treatment?
Valley Spring Recovery Center is an approved provider for Blue Shield of California and Cigna, while also accepting many other major insurance carriers.
Check Coverage Now!
